---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-251014"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:26:11.415560+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcellx updates anito-cel data: Phase 1 median PFS 30.2 months; iMMagine-1 95% ORR

## Summary
- Phase 1 study (38 patients): 100% ORR, 79% CR/sCR, median PFS 30.2 months at 38.1 months median follow-up; median OS not reached.
- iMMagine-1 (58 patients): 95% ORR, 62% CR/sCR, median follow-up 10.3 months; 92% MRD negativity at 10^-5.
- No delayed neurotoxicities (no parkinsonism, no cranial nerve palsies, no Guillain-Barré) observed across >140 patients dosed.
- First patient dosed in iMMagine-3 study (earlier lines); manufactured by Kite with turnaround time in line with Kite's commercial products.
- Data to be presented at ASH Annual Meeting Dec 7-10, 2024; company webcast Dec 9 at 8:30 p.m. PT.

## SEC filing metadata
- accession: 0001193125-24-251014
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312524251014/0001193125-24-251014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312524251014/d844485d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-251014
- JSON: https://secwatch.observer/filing/0001193125-24-251014.json
- Plain text: https://secwatch.observer/filing/0001193125-24-251014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.